237 related articles for article (PubMed ID: 34741118)
1. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.
Dutta A; Nath D; Yang Y; Le BT; Rahman MF; Faughnan P; Wang Z; Stuver M; He R; Tan W; Hutchison RE; Foulks JM; Warner SL; Zang C; Mohi G
Leukemia; 2022 Mar; 36(3):746-759. PubMed ID: 34741118
[TBL] [Abstract][Full Text] [Related]
2. CDK6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract][Full Text] [Related]
3. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm.
Rahman MF; Yang Y; Le BT; Dutta A; Posyniak J; Faughnan P; Sayem MA; Aguilera NS; Mohi G
Nat Commun; 2022 Sep; 13(1):5347. PubMed ID: 36100596
[TBL] [Abstract][Full Text] [Related]
6. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
9. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm.
Yang Y; Akada H; Nath D; Hutchison RE; Mohi G
Blood; 2016 Jun; 127(26):3410-23. PubMed ID: 27081096
[TBL] [Abstract][Full Text] [Related]
10. Increased SLAMF7
Maekawa T; Kato S; Kawamura T; Takada K; Sone T; Ogata H; Saito K; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Horiuchi T; Hikota-Saga R; Endo-Umeda K; Uno S; Osawa Y; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Usuki K; Morishita S; Araki M; Makishima M; Komatsu N; Kimura F
Blood; 2019 Sep; 134(10):814-825. PubMed ID: 31270105
[TBL] [Abstract][Full Text] [Related]
11. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Fuentes-Mattei E; Bayraktar R; Manshouri T; Silva AM; Ivan C; Gulei D; Fabris L; Soares do Amaral N; Mur P; Perez C; Torres-Claudio E; Dragomir MP; Badillo-Perez A; Knutsen E; Narayanan P; Golfman L; Shimizu M; Zhang X; Zhao W; Ho WT; Estecio MR; Bartholomeusz G; Tomuleasa C; Berindan-Neagoe I; Zweidler-McKay PA; Estrov Z; Zhao ZJ; Verstovsek S; Calin GA; Redis RS
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31941838
[TBL] [Abstract][Full Text] [Related]
12. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.
Wernig G; Kharas MG; Mullally A; Leeman DS; Okabe R; George T; Clary DO; Gilliland DG
Leukemia; 2012 Apr; 26(4):720-7. PubMed ID: 22005786
[TBL] [Abstract][Full Text] [Related]
13. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis.
Varricchio L; Iancu-Rubin C; Upadhyaya B; Zingariello M; Martelli F; Verachi P; Clementelli C; Denis JF; Rahman AH; Tremblay G; Mascarenhas J; Mesa RA; O'Connor-McCourt M; Migliaccio AR; Hoffman R
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34383713
[TBL] [Abstract][Full Text] [Related]
14. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
17. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
Bryan JC; Verstovsek S
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
[TBL] [Abstract][Full Text] [Related]
18. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Dunbar AJ; Kim D; Lu M; Farina M; Bowman RL; Yang JL; Park Y; Karzai A; Xiao W; Zaroogian Z; O'Connor K; Mowla S; Gobbo F; Verachi P; Martelli F; Sarli G; Xia L; Elmansy N; Kleppe M; Chen Z; Xiao Y; McGovern E; Snyder J; Krishnan A; Hill C; Cordner K; Zouak A; Salama ME; Yohai J; Tucker E; Chen J; Zhou J; McConnell T; Migliaccio AR; Koche R; Rampal R; Fan R; Levine RL; Hoffman R
Blood; 2023 May; 141(20):2508-2519. PubMed ID: 36800567
[TBL] [Abstract][Full Text] [Related]
19. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
Stein BL; Swords R; Hochhaus A; Giles F
Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
[TBL] [Abstract][Full Text] [Related]
20. Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice.
Ozono Y; Shide K; Kameda T; Kamiunten A; Tahira Y; Sekine M; Akizuki K; Nakamura K; Iwakiri H; Sueta M; Hidaka T; Kubuki Y; Yamamoto S; Hasuike S; Sawaguchi A; Nagata K; Shimoda K
Leukemia; 2021 Feb; 35(2):454-467. PubMed ID: 32472085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
